MedImmune and Medarex entered into research & development agreement for Medarex’s MDX-1103 and MDX-1333 antibodies that are in preclinical trials for treating autoimmune diseases such as systemic lupus erythematosus...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: PharmaDeals Ltd